nephros.com - NEPH Operating profit EBITDA

Nephros, Inc. (NEPH) attracts leading bioengineers due to its strong ESG mission in the field of infection control. The monetary expression of EBITDA confirms the effectiveness of this approach, where the 1.95 mark reflects the latest data. The company is valued by dialysis centers for its impeccable water purity. Stable demand for consumables guarantees a regular inflow of capital without the risk of technological obsolescence.

Profit before payment of interest, taxes and amortization: Nephros Inc (NEPH) for 11/23/2025 - 11/11/2026

Nephros (NEPH) - metric breakdowns and financial figures

- price and consensus price forecast:

Price Rate Chart Nephros Corporation|NEPH - Consensus Target

- issuer market value details:

Market Capitalization Nephros|NEPH - Enterprise Value

- book value of equity indicators:

Net Assets per Share Nephros|NEPH - Company Book Value|Market Capitalization to Net Assets nephros.com|NEPH - Aggregate Company Assets

- business debt structure and liquidity details:

- company profitability and valuation multiples indicators:

NEPH - Net Profit|Expected Net Profit Nephros, Inc.|NEPH - Price to Earnings Ratio|Price to Expected Earnings Ratio nephros.com|NEPH - PEG Multiple|Business Value to Operating Income Before Depreciation Nephros|NEPH - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Nephros|NEPH - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months nephros.com|NEPH - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Nephros, Inc.

Analysis of all company metrics:Nephros Corporation - NEPH

Professional managers utilize fundamental metrics to segregate assets based on their level of operational efficiency. This indicator measures cash flow from core operations before depreciation and taxes, which, combined with stable demand for Nephros, Inc. (NEPH) ultrafiltration systems, allows for an assessment of working capital replenishment rates through EBITDA volatility.

Competitor analysis for Nephros, Inc.